Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Sees Large Drop in Short Interest

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a large decline in short interest in April. As of April 15th, there was short interest totaling 1,633 shares, a decline of 98.7% from the March 31st total of 127,097 shares. Based on an average daily volume of 172,481 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are short sold.

Emmaus Life Sciences Stock Down 2.2%

OTCMKTS:EMMA traded down $0.00 during trading hours on Friday, reaching $0.01. 116,500 shares of the company’s stock were exchanged, compared to its average volume of 52,621. The company has a market capitalization of $624,691.00, a P/E ratio of -0.07 and a beta of 10.82. Emmaus Life Sciences has a 12 month low of $0.01 and a 12 month high of $0.02. The business’s 50-day simple moving average is $0.01 and its two-hundred day simple moving average is $0.01.

Emmaus Life Sciences (OTCMKTS:EMMA) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $3.85 million during the quarter.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.